Journals / Çocuk ve Gençlik Ruh Sağlığı Dergisi / 2021 / Cilt: 28 - Sayı: 2

International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention Deficit Hyperactivity Disorder and Substance Use Disorder

Dikkat Eksikliği Hiperaktivite Bozukluğu ve Madde Kullanım Bozukluğu Eş Tanısı Olan Ergenlerin Taranması, Tanısı ve Tedavisi için Uluslararası Fikir Birliği Beyanı

Pages
79–88
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Routine screening is recommended for ADHD in adolescent patients in substance abuse treatment and for SUD in adolescent patients with ADHD in mental healthcare settings.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Childhood attention deficit hyperactivity disorder (ADHD) is a risk factor for substance misuse and substance use disorder (SUD) in adolescence and (early) adulthood.
📊
Key Findings & Data:To reach a consensus based on the combination of scientific data and clinical experience, a modified Delphi study was conducted with a multidisciplinary group of 55 experts from 17 countries.
💡
Conclusion & Impact:Routine screening is recommended for ADHD in adolescent patients in substance abuse treatment and for SUD in adolescent patients with ADHD in mental healthcare settings.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Childhood attention deficit hyperactivity disorder (ADHD) is a risk factor for substance misuse and substance use disorder (SUD) in adolescence and (early) adulthood. ADHD and SUD also frequently co-occur in treatment-seeking adolescents, which complicates diagnosis and treatment and is associated with poor treatment outcomes. Research on the effect of treatment of childhood ADHD on the prevention of adolescent SUD is inconclusive, and studies on the diagnosis and treatment of adolescents with ADHD and SUD are scarce. Thus, the available evidence is generally not sufficient to justify robust treatment recommendations. The aim of the study was to obtain a consensus statement based on a combination of scientific data and clinical experience. To reach a consensus based on the combination of scientific data and clinical experience, a modified Delphi study was conducted with a multidisciplinary group of 55 experts from 17 countries. The experts were asked to rate a set of statements on the effect of treatment of childhood ADHD on adolescent SUD and on the screening, diagnosis, and treatment of adolescents with comorbid ADHD and SUD. After 3 iterative rounds of rating and adapting 37 statements, consensus was reached on 36 of these statements representing 6 domains: general (n=4), risk of developing SUD (n=3), screening and diagnosis (n=7), psychosocial treatment (n=5), pharmacological treatment (n=11), and complementary treatments (n=7). Routine screening is recommended for ADHD in adolescent patients in substance abuse treatment and for SUD in adolescent patients with ADHD in mental healthcare settings. Long-acting stimülants are recommended as the first-line treatment of ADHD in adolescents with concurrent ADHD and SUD, and pharmacotherapy should preferably be embedded in psychosocial treatment. The only remaining noconsensus statement concerned the requirement of abstinence before starting pharmacological treatment in adolescents with ADHD and concurrent SUD. In contrast to the majority, some experts required full abstinence before starting any pharmacological treatment, some were against the use of stimülants in the treatment of these patients (independent of abstinence), while some were against the alternative use of bupropion. This international consensus statement can be used by clinicians and patients together in a shared decision-making process to select the best interventions and to reach optimal outcomes in adolescent patients with concurrent ADHD and SUD.

Özet

Çocukluk çağı dikkat eksikliği hiperaktivite bozukluğu (DEHB) ergenlik ve (erken) yetişkinlikte madde kötüye kullanımı ve madde kullanımbozukluğu (MKB) için bir risk faktörüdür. Ayrıca, DEHB ve MKB tedavi arayan ergenlerde sıklıkla birlikte görülmektedir, bu durum tanı vetedaviyi karmaşıklaştırır ve azalmış tedavi yanıtları ile ilişkilidir. Çocukluk çağı DEHB tedavisinin ergenlik dönemindeki MKB’nin önlenmesindekietkisine yönelik araştırmalar sonuca ulaşmamaktadır ve DEHB ve MKB eş tanılı ergenlerin tanı ve tedavisine yönelik çalışmalar çok azdır.Bu nedenle, mevcut kanıtlar genel olarak güçlü tedavi önerileri sunmak için yeterli değildir. Bu çalışmanın amacı, bilimsel veriler ve klinikdeneyimin bir birleşimine dayalı bir fikir birliği beyanı elde etmektir. Bilimsel veriler ve klinik deneyimin birleşimine dayanan bir fikir birliğinevarmak için 17 ülkeden 55 uzmandan oluşan multi-disipliner bir grupla modifiye edilmiş bir Delphi çalışması yürütülmüştür. Uzmanlardan,çocukluk çağı DEHB tedavisinin ergenlik dönemindeki MKB üzerindeki etkisine ve DEHB ve MKB eş tanısı olan ergenlerin tarama, tanı vetedavisine ilişkin bir dizi ifadeyi derecelendirmeleri istenmiştir. Üç yinelemeli derecelendirme turundan ve 37 ifadeyi uyarladıktan sonra, 6 alanıtemsil eden bu ifadelerin 36’sı üzerinde fikir birliğine varılmıştır; genel (n=4), MKB geliştirme riski (n=3), tarama ve tanı (n=7), psikososyaltedavi (n=5), farmakolojik tedavi (n=11) ve tamamlayıcı tedaviler (n=7). Madde bağımlılığı tedavisi gören ergen hastalarda DEHB için veruh sağlığı kliniklerinde DEHB nedeniyle takipte olan ergen hastalarda MKB için rutin tarama önerilmektedir. DEHB ve MKB eş tanısı olanergenlerde DEHB’nin birinci basamak tedavisi olarak uzun etkili stimülanlar önerilmektedir ve farmakoterapi tercihen psikososyal tedaviyedahil edilmelidir. Geriye kalan tek fikir birliği olmayan ifade, DEHB ve MKB eş tanısı olan ergenlerde farmakolojik tedaviye başlamadanönce maddeden yoksun kalma gerekliliğiyle ilgilidir. Çoğunluğun aksine, bazı uzmanlar herhangi bir farmakolojik tedaviye başlamadan öncetamamen yoksun kalmayı gerekli bulurken, bazıları bu hastaların tedavisinde stimülanların kullanımına karşıdır (yoksunluktan bağımsızolarak), bazıları ise alternatif olarak bupropion kullanımına karşı görüş bildirmiştir. Bu uluslararası fikir birliği beyanı, DEHB ve MKB eş tanısıolan ergen hastalarda en iyi müdahaleleri seçmek ve optimal sonuçlara ulaşmak için klinisyenler ve hastalar tarafından ortak bir karar almasürecinde kullanılabilir.

🔖

Cite This Article

ÖZGEN, M. H., BOLAT, G. Ü., SPİJKERMAN, R., BRİNK, W. V. D., HENDRİKS, V., ERCAN, E. S., EMİROĞLU, N. İ. (2021). International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention Deficit Hyperactivity Disorder and Substance Use Disorder. Çocuk ve Gençlik Ruh Sağlığı Dergisi, Cilt: 28 - Sayı: 2, 79–88. https://ajindex.com/articles/348552

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, Smit F, Crunelle CL, Swets M, Schoevers RA. Prevalence of attentiondeficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend. 2012;12:11-9
  2. Wilens TE, Morrison NR. Substance-use disorders in adolescents and adults with ADHD: focus on treatment. Neuropsychiatry (London). 2012;2:301-12
  3. Groenman AP, Oosterlaan J, Rommelse N, Franke B, Roeyers H, Oades RD, Sergeant JA, Buitelaar JK, Faraone SV. Substance use disorders in adolescents with attention deficit hyperactivity disorder: a 4-year follow-up study. Addiction. 2013;108:1503-11
  4. Groenman AP, Janssen TWP, Oosterlaan J. Childhood Psychiatric Disorders as Risk Factor for Subsequent Substance Abuse: A MetaAnalysis. J Am Acad Child Adolesc Psychiatry. 2017;56:556-69
  5. Groenman AP, Schweren LJS, Weeda W, Luman M, Noordermeer SDS, Heslenfeld DJ, Franke B, Faraone SV, Rommelse N, Hartman CA, Hoekstra PJ, Buitelaar J, Oosterlaan J. Stimülant treatment profiles predicting co-occurring substance use disorders in individuals with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2019;28:1213-22
  6. Quinn PD, Chang Z, Hur K, Gibbons RD, Lahey BB, Rickert ME, Sjölander A, Lichtenstein P, Larsson H, D'Onofrio BM. ADHD Medication and Substance-Related Problems. Am J Psychiatry. 2017;174:877-85
  7. Humphreys KL, Eng T, Lee SS. Stimülant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry. 2013;70:740-9
  8. Molina BS, Hinshaw SP, Eugene Arnold L, Swanson JM, Pelham WE, Hechtman L, Hoza B, Epstein JN, Wigal T, Abikoff HB, Greenhill LL, Jensen PS, Wells KC, Vitiello B, Gibbons RD, Howard A, Houck PR, Hur K, Lu B, Marcus S; MTA Cooperative Group. Adolescent substance use in the multimodal treatment study of attentiondeficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry. 2013;52:250-63
  9. Landelijke Stuurgroep Multidisciplinaire richtlijnontwikkeling in de GGZ. Multidisciplinaire Richtlijn ADHD bij Kinderen en Jeugdigen. Utrecht: Trimbos-Instituut; 2005
  10. The Royal Australasian College of Physicians (RACP). Draft Australian Guidelines on Attention Deficit Hyperactivity Disorder (ADHD). 2009. Available from: https://www.racp.edu.au/docs/default-source/ advocacylibrary/pa-australian-guidelines-on-adhddraft.